Home › Funds › Deep Track Capital, LP › ALNY
Deep Track Capital, LP position in ALNY
ALNYLAM PHARMACEUTICALS INC · Health Care
Deep Track Capital, LP reported holding 825,000 shares of ALNY (ALNYLAM PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$248.3M, representing 3.70% of its reported portfolio and ranking #5 among its reported holdings. Deep Track Capital, LP has disclosed ALNY holdings in 3 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Deep Track Capital, LP's ALNY position evolved
Deep Track Capital, LP first disclosed a stake in ALNY in Q1 2024 at 832,310 shares (US$124.4M). The position peaked in Q2 2026 at 825,000 shares, worth US$248.3M. Across 3 filings, Deep Track Capital, LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 825,000 shares valued at US$248.3M. Notable position changes include a 40% trim in Q2 2024 (shares rose 13% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 832.31K | $124.39M | New |
| Q2 2024 | 500.00K | $121.50M | Reduce |
| Q2 2026 | 825.00K | $248.35M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ALNY and 13F data
ALNY (ALNYLAM PHARMACEUTICALS INC) is a Health Care company. 35 other funds we track also report a position in ALNY — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.70B), Baillie Gifford & Co (US$734.5M), Orbis Allan Gray Ltd (US$598.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ALNY
- T. Rowe Price Investment Management, Inc. 5.64M sh · $1.70B · Q2 2026
- Baillie Gifford & Co 2.44M sh · $734.48M · Q2 2026
- Orbis Allan Gray Ltd 1.99M sh · $598.27M · Q2 2026
- Two Sigma Investments 1.88M sh · $564.71M · Q2 2026
- AMERICAN CENTURY COMPANIES INC 1.85M sh · $558.10M · Q2 2026
- TWO SIGMA ADVISERS, LP 1.13M sh · $450.36M · Q4 2025
- Qube Research & Technologies Ltd 798.72K sh · $240.44M · Q2 2026
- LOS ANGELES CAPITAL MANAGEMENT LLC 729.63K sh · $219.64M · Q2 2026
- LOOMIS SAYLES & CO L P 580.19K sh · $174.65M · Q2 2026
More on Deep Track Capital, LP
FAQ
How long has Deep Track Capital, LP held ALNY?
Deep Track Capital, LP has disclosed ALNY holdings in 3 of the last 10 reported quarters, going back to Q1 2024.
What is Deep Track Capital, LP's current position in ALNY?
As of Q2 2026, Deep Track Capital, LP holds 825.00K shares of ALNY (ALNYLAM PHARMACEUTICALS INC), valued at $248.35M, representing 3.70% of its reported portfolio and ranking #5.
Has Deep Track Capital, LP been buying or selling ALNY?
In the latest 13F filing (Q2 2026), Deep Track Capital, LP newly opened its position in ALNY. The position peaked in Q2 2026 at 825.00K shares.
Which other funds hold ALNY?
Other major institutional holders of ALNY include T. Rowe Price Investment Management, Inc., Baillie Gifford & Co, Orbis Allan Gray Ltd, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.